ADCC has been proven as the major mechanism of the innate immune system against antigen-expressing cancer cells [16, 17], and the main anti-tumor effect of therapeutic antibodies is predominately mediated by NK cells, which express FcγRIII (CD16) [18, 19]. Here, FCGR3A is linked to cancer.